Oct 30, 2026 07:00AM
Oct 30, 2026 12:15AM
Sep 13, 2026 09:45PM
Sep 13, 2026 09:45PM
Aug 26, 2026 07:00AM
Aug 26, 2026 07:00AM
Aug 17, 2026 02:30AM Enhertu meets main goal in phase 3 lung cancer trial
Aug 17, 2026 02:30AM
Jul 31, 2026 04:30AM
May 22, 2026 09:30AM
May 22, 2026 08:00AM
May 22, 2026 08:00AM
May 15, 2026 06:31PM
Apr 13, 2026 07:00AM Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Bas
Apr 1, 2026 08:01AM
Apr 1, 2026 08:00AM
Mar 9, 2026 02:30AM
Feb 19, 2026 02:30AM
Feb 3, 2026 02:30AM
Jan 19, 2026 02:30AM
Jan 13, 2026 07:00AM Daiichi Sankyo initiates phase 3 lung cancer trial with biomarker selection
Jan 13, 2026 07:00AM
Dec 22, 2025 02:30AM
Dec 22, 2025 02:30AM
Dec 22, 2025 02:30AM
Dec 15, 2025 02:30PM
Dec 15, 2025 02:30PM
Dec 15, 2025 09:00AM Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
Dec 9, 2025 07:01AM
Dec 9, 2025 07:00AM
Oct 30, 2025 09:00PM
Oct 30, 2025 09:00PM
Oct 19, 2025 08:45AM
Oct 19, 2025 08:45AM
Oct 19, 2025 02:30AM DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom
Oct 18, 2025 10:30AM
Oct 18, 2025 10:30AM
Oct 18, 2025 10:30AM
Oct 18, 2025 10:30AM
Oct 17, 2025 10:00AM
Oct 17, 2025 10:00AM
Oct 6, 2025 02:30AM DATROWAY® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Im
Oct 1, 2025 07:00AM
Oct 1, 2025 07:00AM
Sep 29, 2025 02:30AM
Sep 29, 2025 02:30AM
Sep 24, 2025 02:30AM
Sep 15, 2025 07:00AM
Sep 7, 2025 10:45AM Daiichi Sankyo and Merck report phase 2 trial results for lung cancer drug
Sep 7, 2025 10:45AM

336,289 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All